Key result
Adding curcumin to abemaciclib lowers liver enzymes, lipids, and fibrosis markers vs abemaciclib alone.
Why the study?
Abemaciclib is an important antitumor agent for breast cancer, but its hepatic side-effects are unclear, prompting investigation into whether curcumin protects against abemaciclib-induced liver damage.
Does curcumin prevent liver damage and lipid profile alterations caused by abemaciclib in rats?
Does curcumin prevent liver damage and lipid profile alterations caused by abemaciclib in rats?
p-value: p=< 0.05
Curcumin may serve as a therapeutic agent to prevent abemaciclib-induced liver damage and lipid profile alterations.
Hypothesis-generating for curcumin mitigating abemaciclib hepatotoxicity; leaves open translation to human use.
Abemaciclib (ABEM) is an important antitumor agent for breast cancer treatment. However, the side-effects of ABEM are unclear in the liver. This study investigated the protective effect of curcumin (CURC) on liver damage caused by ABEM. The rats were divided into five groups with eight animals in each group; Control, DMSO (150 µL for per rats), CURC, 30 mg/kg/day), ABE (26 mg/kg/day), and ABE + CURC (26 mg/kg/day ABE, 30 mg/kg/day) groups. Injections were administered daily for 28 days. The levels of AST, LDH, HDL, LDL, triglyceride, and total cholesterol in serum, and hepatic tissue fibrosis, caspase-3, Bax, and TNF-α expression were higher in the ABE group compared to the control group (p < 0.05). Also, these parameters in the ABEM + CURC group were lower than in the ABE group (p < 0.05). The results showed that ABE administration could cause liver damage and increase fibrosis in the liver. In addition, it was shown that co-administration of CURC with ABE could suppress the levels of AST, LDH, HDL, LDL, triglyceride, and total cholesterol in serum, and fibrosis, caspase-3, Bax, and TNF-α expressions in the liver. These data are the first in the literature. Therefore, the administration of CURC following ABE may be a therapeutic agent in preventing liver damage.
No takes yet. Share an insight, caveat, or question.
Huyut et al. (2022) studied Abemaciclib-induced liver damage (n=40). Curcumin vs. Abemaciclib alone was evaluated on Serum levels of AST, LDH, HDL, LDL, triglyceride, total cholesterol, and hepatic tissue fibrosis, caspase-3, Bax, and TNF-α expression (p=< 0.05). Co-administration of curcumin with abemaciclib significantly lowered serum liver enzymes, lipids, and hepatic fibrosis and apoptosis markers compared to abemaciclib alone (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: